What were your highlights from ASH 2023?
AML Hub
by Scientific Education Support
2M ago
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub.  Hosted on Acast. See acast.com/privacy for more information ..read more
Visit website
What are the challenges associated with CAR T-cell therapy in patients with AML?
AML Hub
by Scientific Education Support
2M ago
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therapy in patients with AML?  Hosted on Acast. See acast.com/privacy for more information ..read more
Visit website
How might the MORPHO trial of gilteritinib impact clinical practice?
AML Hub
by Scientific Education Support
3M ago
The AML Hub spoke to Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK at ASH 2023. We asked, How might the MORPHO trial of gilteritinib impact clinical practice? Hosted on Acast. See acast.com/privacy for more information ..read more
Visit website
Risk stratification and guidelines in AML management
AML Hub
by Scientific Education Support
6M ago
The AML Hub was pleased to speak to Gail Roboz, Weill Cornell Medicine, New York, US, and Naval Daver, MD Anderson Cancer Center, Houston, US. We asked about risk stratification and guidelines in acute myeloid leukemia (AML) management.   Firstly, Roboz and Daver discuss the impact of blast count on the diagnosis of AML and how a patient's mutational profile can affect treatment decisions. They highlight available, effective lower-intensity and targeted therapies and a potential transition to a fully genomic- and cytogenetic-based classification of AML. Finally, they discuss current ..read more
Visit website
Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML
AML Hub
by Scientific Education Support
1y ago
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Courtney D. DiNardo, MD Anderson Cancer Center, Houston, US, about the use of venetoclax combinations in mutation subtypes of AML. In this podcast, DiNardo gives an overview of the studies on venetoclax combinations presented at ASH 2020, especially venetoclax plus azacitidine, in mutation subtypes of AML. DiNardo focuses on three specific subgroups: patients with IDH1/2 mutations; patients with FLT3 mutations; and patients with TP53 mutations. After talking about the promising results re ..read more
Visit website
How are new fludarabine conditioning combinations impacting transplant outcomes?
AML Hub
by Scientific Education Support
2y ago
During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessaloniki, Thessaloniki, GR. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes? Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of fludarabine + treosulfan, which followed on from previous studies exploring treosulfan. Gavriilaki details the study design and patient population, explaining which comparative therapies were used a ..read more
Visit website
Should pre-transplant MRD be used to guide treatment in AML?
AML Hub
by Scientific Education Support
3y ago
During the EHA2021 Virtual Congress, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)? Craddock begins by outlining the reasons for the increased use of allogeneic transplant and reviews data that discuss the exclusion criteria and benefits of transplant. He goes on to discuss how patient outcomes could be improved and the importance of post-transplant maintenance. Finally, he highlights the need to generate prospective dat ..read more
Visit website
Should pre-transplant MRD be used to guide treatment in AML?
AML Hub
by Scientific Education Support
3y ago
During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatment in AML? Nagler begins by discussing the importance of MRD in AML treatment and transplantation. He highlights the significance of MRD in different settings as a prognosis factor and describes the result of his study presented at EHA2021. Finally, he outlines the current treatment landscape for transplants in relation to MRD status and makes recommendations for MRD-positive patients. See acast ..read more
Visit website
Should pre-transplant MRD be used to guide treatment in AML?
AML Hub
by Scientific Education Support
3y ago
During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)? Ossenkoppele begins by outlining emerging techniques in MRD, such as next-generation sequencing. He goes on to describe how risk category and MRD status can inform treatment decisions, such as for allogeneic stem cell transplant. See acast.com/privacy for privacy and opt-out information ..read more
Visit website
Can HMA maintenance therapy improve eligibility for HSCT?
AML Hub
by Scientific Education Support
3y ago
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT?   Ravandi begins by highlighting the limited maintenance approaches for patients with AML. He continues with the promising results from the QUAZAR AML-001 study evaluating oral azacitidine (CC-486), an oral hypomethylating agent, which can be used for maintenance and to improve eligibility for hematopoietic stem cell transplantation. See acast.com/privacy for privacy and opt-out information ..read more
Visit website

Follow AML Hub on FeedSpot

Continue with Google
Continue with Apple
OR